Browse News
Filter News
Found 804,914 articles
-
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
3/19/2024
Asieris Pharmaceuticals announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18.
-
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
3/19/2024
Vicore Pharma Holding AB announced FDA Breakthrough Device Designation status for AlmeeTM, a 9-week digital cognitive behavioral therapy, to be used as an adjunct treatment of anxiety symptoms related to PF.
-
CGI selected by Centers for Medicare & Medicaid Services to improve Medicare access for more than 65 million beneficiaries nationwide
3/19/2024
CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency's Health Plan Management System.
-
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
3/19/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
3/19/2024
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.
-
Solventum Hosts Inaugural Investor Day Ahead of Its Planned Spinoff from 3M
3/19/2024
Solventum will host its inaugural Investor Day in New York City ahead of its planned spinoff from 3M.
-
Biovica rReceives Positive Patent Notification for Immunotherapies
3/19/2024
Biovica International Biovica has received a positive International Preliminary Report on Patentability covering the use of TKa as a prognostic and monitoring marker in cancer treatment outside the CDK 4/6 inhibitor space, expanding the market potential for the DiviTum TKa technology by four to six times.
-
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
3/19/2024
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.
-
PureTech Proposes $100 Million Capital Return
3/19/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces a proposed capital return of $100 million to its shareholders by way of a tender offer.
-
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
3/19/2024
Portal Biotechnologies, Inc., a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
-
IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson’s Disease Psychosis
3/19/2024
IRLAB Therapeutics AB announced that a scientific paper reporting the effects of IRLAB's candidate drug mesdopetam in a preclinical model of Parkinson's disease psychosis has been published in the journal Neurotherapeutics.
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
3/19/2024
Innovent Biologics, Inc. announced that the primary endpoint has been met in the second Phase 2 clinical study of efdamrofusp alfa high-dose, a recombinant human VEGFR-Fc-Human CR1 fusion protein injection, in Chinese subjects with neovascular age-related macular degeneration.
-
Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo
3/19/2024
Cognizant is advancing the application of generative AI technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.
-
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
3/19/2024
Opthea Limited announced it will host a virtual key opinion leader event on Wednesday, April 3, 2024, from 10:00 to 11:30 am ET, featuring presentations from global retina experts:
-
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
3/19/2024
Crinetics Pharmaceuticals, Inc. announced positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
-
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
3/19/2024
Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
-
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
3/19/2024
Fennec Pharmaceuticals Inc. announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024.
-
Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024
3/19/2024
Innate Pharma SA announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.
-
Telum Therapeutics appoints Dr. Subhendu Basu as CEO
3/19/2024
Telum Therapeutics is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer.
-
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease
3/19/2024
BioArctic AB announced that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer's disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18.